UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000041339 |
|---|---|
| Receipt number | R000047176 |
| Scientific Title | Analysis of anti-tumor immunosuppressive mechanism of dendritic cells in pediatric solid tumors |
| Date of disclosure of the study information | 2020/08/20 |
| Last modified on | 2024/09/17 07:38:59 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Analysis of anti-tumor immunosuppressive mechanism of dendritic cells in pediatric solid tumors
Acronym
Analysis of anti-tumor immunosuppressive mechanism of dendritic cells in pediatric solid tumors
Scientific Title
Analysis of anti-tumor immunosuppressive mechanism of dendritic cells in pediatric solid tumors
Scientific Title:Acronym
Analysis of anti-tumor immunosuppressive mechanism of dendritic cells in pediatric solid tumors
Region
| Japan |
Condition
Condition
Healthy volunteers
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
YES
Objectives
Narrative objectives1
This study aims to elucidate the anti-tumor immunosuppression mechanism of dendritic cells in tumor microenvironments
Basic objectives2
Others
Basic objectives -Others
The goal of this study is the development of a new treatment to release anti-tumor immunosuppression
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
None
Key secondary outcomes
Base
Study type
Others,meta-analysis etc
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 60 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1) Age: Between 20 and 60 years old.
2) Healthy adults with no history of past pediatric solid tumors
3) Those who acknowledge to understand the terms and conditions of this study, and sign study participant agreement of their own free will, after receiving sufficient explanation on participation in this study.
Key exclusion criteria
We exclude participants from whom it is difficult to collect blood (in cases where participants' conditions are significantly poor, or it is difficult to collect blood from participants technically).
Target sample size
30
Research contact person
Name of lead principal investigator
| 1st name | Shinichiro |
| Middle name | |
| Last name | Motohashi |
Organization
Graduate school of Medicine, Chiba University
Division name
Department of Medical Immunology
Zip code
2608670
Address
1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, Japan
TEL
043-222-7171
motohashi@faculty.chiba-u.jp
Public contact
Name of contact person
| 1st name | Shinichiro |
| Middle name | |
| Last name | Motohashi |
Organization
Graduate school of Medicine, Chiba University
Division name
Department of Medical Immunology
Zip code
2608670
Address
1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, Japan
TEL
043-222-7171
Homepage URL
motohashi@faculty.chiba-u.jp
Sponsor or person
Institute
Chiba University
Institute
Department
Personal name
Funding Source
Organization
Grants in Aid for Young Scientists
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Clinical Research Ethics Committee of the Graduate School of Medicine, Chiba University
Address
1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, Japan
Tel
043-222-7171
m_maekawa@chiba-u.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2020 | Year | 08 | Month | 20 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2018 | Year | 06 | Month | 24 | Day |
Date of IRB
| 2018 | Year | 08 | Month | 28 | Day |
Anticipated trial start date
| 2018 | Year | 09 | Month | 01 | Day |
Last follow-up date
| 2026 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
stored period of dendritic cells
Management information
Registered date
| 2020 | Year | 08 | Month | 06 | Day |
Last modified on
| 2024 | Year | 09 | Month | 17 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047176
